Skip to main content
SpringerLink
Log in

Clinical Pharmacokinetics of Zidovudine

An Update

  • Review Article
  • Drug Disposition
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

The battle against the acquired immune deficiency syndrome (AIDS) is now into its second decade, and substantial advancements have been made in our understanding of the complex life cycle of, and the immunopathology associated with, human immunodeficiency virus (HIV) infection, as well as of the drugs used to modify the course of disease.

Zidovudine was the first agent approved for treatment of HIV disease, and since its widespread availability in 1987 the pharmacokinetic disposition and clinical effects of zidovudine have been extensively evaluated. This article reviews the absorption, distribution, metabolism and elimination characteristics of zidovudine, focusing on more recent information. In addition, factors that may or may not affect zidovudine disposition are discussed. These include selected drug interactions and concomitant disease states such as renal and hepatic insufficiency. Issues such as bodyweight normalisation, maternal-fetal transfer, pregnancy and intracellular phosphorylation are discussed in relation to the pharmacokinetics and clinical efficacy of zidovudine.

Finally, information regarding the clinical pharmacodynamics of zidovudine is presented. This includes possible relationships between zidovudine pharmacokinetics and markers of efficacy and toxicity, and the significance of linking pharmacokinetic and pharmacodynamic information.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fischl M, Richman D, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987; 317: 185–91

    Article  PubMed  CAS  Google Scholar 

  2. Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of mildly symptomatic human immunodeficiency virus type I (HIV) infection: a double-blind, placebo-controlled trial. Ann Intern Med 1990; 112: 727–37

    PubMed  CAS  Google Scholar 

  3. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990; 322: 941–9

    Article  PubMed  CAS  Google Scholar 

  4. Volberding PA, Lagakos SW, Grimes JM, et al. The duration of zidovudine benefit in persons with asymptomatic HIV infection: prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA 1994; 272: 437–42

    Article  PubMed  CAS  Google Scholar 

  5. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331: 1173–80

    Article  PubMed  CAS  Google Scholar 

  6. Klecker RW, Collins JM, Yarchoan R, et al. Plasma and cerebrospinal fluid concentrations of 3′-azido-3′-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther 1987; 41: 407–12

    Article  PubMed  Google Scholar 

  7. Macnab KA, Gill MJ, Sutherland LR, et al. Erratic zidovudine bioavailability in HIV seropositive patients. J Antimicrob Chemother 1993; 31: 421–8

    Article  PubMed  CAS  Google Scholar 

  8. Ehrenpreis ED, Gulino SP, Patterson BK, et al. Kinetics of Dxylose absorption in patients with human immunodeficiency virus enteropathy. Clin Pharmacol Ther 1991; 49: 632–40

    Article  PubMed  CAS  Google Scholar 

  9. Fletcher CV, Rhame FS, Beatty CC, et al. Comparative pharmacokinetics of zidovudine in healthy volunteers and in patients with AIDS with and without hepatic disease. Pharmacotherapy 1992; 12: 429–34

    PubMed  CAS  Google Scholar 

  10. Blum MR, Liao SHT, Good SS, et al. Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med 1988; 85 Suppl. 2a: 189–94

    PubMed  CAS  Google Scholar 

  11. Bareggi S, Cinque P, Mazzei M, et al. Pharmacokinetics of zidovudine in HIV-positive patients with liver disease. J Clin Pharmacol 1994; 34: 782–6

    PubMed  CAS  Google Scholar 

  12. Gitterman SR, Drusano GL, Egorin MJ, et al. Population pharmacokinetics of zidovudine. Clin Pharmacol Ther 1990; 48: 161–7

    Article  PubMed  CAS  Google Scholar 

  13. Luzier A, Morse GD. Intravascular distribution of zidovudine: role of plasma proteins and whole blood components. Antiviral Res 1993; 21: 267–80

    Article  PubMed  CAS  Google Scholar 

  14. Tartaglione TA, Collier AC, Coombs RW, et al. Cerebrospinal fluid findings in patients before and during long-term oral zidovudine therapy. Arch Neurol 1991; 48: 695–9

    Article  PubMed  CAS  Google Scholar 

  15. Balis FM, Pizzo PA, Murphy RF, et al. The pharmacokinetics of zidovudine administered by continuous infusion in children. Ann Intern Med 1989; 110: 279–85

    PubMed  CAS  Google Scholar 

  16. Henry K, Chinnock BJ, Quinn RP, et al. Concurrent zidovudine levels in semen and serum determined by radioimmunoassay in patients with AIDS or AIDS-related complex. JAMA 1988; 259: 3023–6

    Article  PubMed  CAS  Google Scholar 

  17. Ruff A, Hamzeh F, Lietman P, et al. Excretion of zidovudine (ZDV) in human breast milk [abstract 111]. In: The 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1994 Oct 4–7: Orlando, Florida

  18. Sahai J, Gallicano K, Garber G, et al. Relationship between body weight, body surface area and serum zidovudine pharmacokinetic parameters in adult, male HIV-infected patients. AIDS 1994: 8; 793–6

    Article  PubMed  CAS  Google Scholar 

  19. Unadkat J, Tartaglione T, Opheim K, et al. Estimation of population pharmacokinetic parameters of zidovudine (ZDV or AZT) from AIDS patients enrolled in a phase II/III trial [abstract 3640]. In: Proceedings of the Fourth International Conference on AIDS; 1992 June 12–16: Stockholm, Sweden

  20. Burger DM, Meenhorst PL, ten Napal CHH, et al. Pharmacokinetic variability of zidovudine in HIV-infected individuals: subgroup analysis and drug interactions. AIDS 1994; 8: 1683–9

    Article  PubMed  CAS  Google Scholar 

  21. Mentré F, Escolano S, Diquet B, et al. Clinical pharmacokinetics of zidovudine: inter and intraindividual variability and relationships to long term efficacy and toxicity. Eur J Clin Pharmacol 1993; 45: 397–407

    Article  PubMed  Google Scholar 

  22. Fletcher CV, Balfour Jr HH. Variability in zidovudine serum concentrations. Pharmacotherapy 1996. In press

  23. Noormohamed SE, Henry WK, Rhame FS, et al. Strategies for the control of zidovudine serum concentrations. Antimicrob Agents Chemother 1995; 39: 2792–7

    Article  PubMed  CAS  Google Scholar 

  24. Bawdon RE, Sobhi S, Dax JP. The transfer of anti-human immunodeficiency virus nucleoside compounds by the term human placenta. Am J Obstet Gynecol 1992; 167: 1570–4

    PubMed  CAS  Google Scholar 

  25. Schenker S, Johnson RF, King TS, et al. Azidothymidine (zidovudine) transport by the human placenta. Am J Med Sci 1990; 299: 16–20

    Article  PubMed  CAS  Google Scholar 

  26. O’Sullivan MJ, Boyer PJJ, Scott GB, et al. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Am J Obstet Gynecol 1993; 168: 1510–6

    PubMed  Google Scholar 

  27. Good SS, Durack DT, de Miranda P. Biotransformation in various species and in humans of 3′-azido-3′-deoxythymidine, a potential agent for the treatment of AIDS [abstract 1690]. Fed Proc 1986; 45: 444

    Google Scholar 

  28. Howe JL, Back DJ, Colbert J. Extrahepatic metabolism of zidovudine. Br J Clin Pharmacol 1992; 33: 190–2

    Article  PubMed  CAS  Google Scholar 

  29. Dudley MN. Clinical pharmacokinetics of nucleoside antiretroviral agents. J Infect Dis 1995; 171 Suppl. 2: 99S–112S

    Article  Google Scholar 

  30. Stagg MP, Cretton EM, Kidd L, et al. Clinical pharmacokinetics of 3′-azido-3′-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3′-amino-3′-deoxythymidine. Clin Pharmacol Ther 1992; 51: 668–76

    Article  PubMed  CAS  Google Scholar 

  31. Cretton EM, Xie M, Bevan RJ, et al. Catabolism of 3′-azido-3′-deoxythymidine in hepatocytes and liver microsomes with evidence of formation of 3′-amino-3′-deoxythymidine, a highly toxic catabolite for human bone marrow cells. Mol Pharmacol 1990; 39: 258–66

    Google Scholar 

  32. Taburet AM, Naveau S, Zorza G, et al. Pharmacokinetics of zidovudine in patients with liver cirrhosis. Clin Pharmacol Ther 1990; 47: 731–9

    Article  PubMed  CAS  Google Scholar 

  33. Singlas E, Pioger JC, Taburet AM, et al. Zidovudine disposition in patients with severe renal impairment: influence of haemodialysis. Clin Pharmacol Ther 1989; 46: 190–7

    Article  PubMed  CAS  Google Scholar 

  34. Stretcher BN, Pesce AJ, Frame PT, et al. Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1994; 38: 1541–7

    Article  PubMed  CAS  Google Scholar 

  35. Barry M, Wild M, Veal G, et al. Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers. AIDS 1994; 8: F1–5

    Article  PubMed  CAS  Google Scholar 

  36. Robbins BL, Rodman J, McDonald C, et al. Enzymatic assay for measurement of zidovudine triphosphate in peripheral blood mononuclear cells. Antimicrob Agents Chemother 1994; 38: 115–21

    Article  PubMed  CAS  Google Scholar 

  37. Slusher JT, Kuwahara SK, Hamzeh FM, et al. Intracellular zidovudine (ZDV) and ZDV phosphates as measured by a validated combined high-pressure liquid chromatographyradioimmunoassay procedure. Antimicrob Agents Chemother 1992; 36: 2473–7

    Article  PubMed  CAS  Google Scholar 

  38. Unadkat JD, Collier AC, Crosby SS, et al. Pharmacokinetics of oral zidovudine (azidothymidine) in patients with AIDS when administered with and without a high-fat meal. AIDS 1990; 4: 229–32

    Article  PubMed  CAS  Google Scholar 

  39. Ruhnke M, Bauer FE, Seifert M, et al. Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS. Antimicrob Agents Chemother 1993; 37: 2153–8

    Article  PubMed  CAS  Google Scholar 

  40. Sahai J, Gallicano K, Garber G, et al. The effect of a protein meal on zidovudine pharmacokinetics in HIV-infected patients. Br J Clin Pharmacol 1992; 33: 657–60

    Article  PubMed  CAS  Google Scholar 

  41. Lotterer B, Ruhnke M, Trautmann M, et al. Decreased and variable systemic availability of zidovudine in patients with AIDS if administered with a meal. Eur J Clin Pharmacol 1991; 40: 305–8

    Article  PubMed  CAS  Google Scholar 

  42. Burger DM, Meenhorst PL, Koks CHW, et al. Pharmacokinetic interaction between rifampin and zidovudine. Antimicrob Agents Chemother 1993; 37: 1426–31

    Article  PubMed  CAS  Google Scholar 

  43. Narang PK, Sale M. Population based assessment of rifabutin effect on zidovudine disposition in AIDS patients [abstract]. Clin Pharmacol Ther 1993; 53: 219

    Google Scholar 

  44. Gallicano K, Sahai J, Swick L, et al. The effect of rifabutin (R) on zidovudine (Z) pharmacokinetics in HIV+ patients [abstract 486]. The 2nd National Conference on Human Retro-viruses and Related Infections; 1995 Jan 29–Feb 2: Washington, DC

  45. Lavrijsen KLM, Van Houdt JMG, Van Dyck DMJ, et al. Induction potential of fluconazole toward drug metabolizing enzymes in rats. Antimicrob Agents Chemother 1990; 34: 402–8

    Article  PubMed  CAS  Google Scholar 

  46. Sahai J, Gallicano K, Pakuts A, et al. Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. J Infect Dis 1994; 169: 1103–7

    Article  PubMed  CAS  Google Scholar 

  47. de Miranda P, Good SS, Yarchoan R, et al. Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex. Clin Pharmacol Ther 1989; 46: 494–500

    Article  PubMed  Google Scholar 

  48. Weiner IM, Mudge GH. Renal tubular mechanisms for excretion of organic acids and bases. Am J Med 1964; 36: 743–62

    Article  PubMed  CAS  Google Scholar 

  49. Fletcher CV, Henry K, Noormohamed SE, et al. The pharmacologic effect of H2-antagonists with zidovudine. Pharmacotherapy 1995; 15: 701–8

    PubMed  CAS  Google Scholar 

  50. Watts DH, Brown ZA, Tartaglione T, et al. Pharmacokinetic disposition of zidovudine during pregnancy. J Infect Dis 1991; 163: 226–32

    Article  PubMed  CAS  Google Scholar 

  51. Balis FM, Pizzo PA, Eddy J, et al. Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection. J Pediatr 1989; 114: 880–4

    Article  PubMed  CAS  Google Scholar 

  52. Boucher FD, Modlin JF, Weiler S, et al. Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. J Pediatr 1993; 122: 137–44

    Article  PubMed  CAS  Google Scholar 

  53. Sale M, Sheiner LB, Volberding P, et al. Zidovudine response relationships in early human immunodeficiency virus infection. Clin Pharmacol Ther 1993; 54: 556–66

    Article  PubMed  CAS  Google Scholar 

  54. Drusano GL, Balis FM, Gitterman SR, et al. Quantitative relationships between zidovudine exposure and efficacy and toxicity. Antimicrob Agents Chemother 1994; 38: 1726–31

    Article  PubMed  CAS  Google Scholar 

  55. Fletcher CV, Acosta EP, Henry K, et al. Concentration-controlled zidovudine (ZDV) therapy: preliminary safety, virologic, and immunologic results [abstract 353]. In: The Third Conference on Retroviruses and Opportunistic Infections; 1996 Jan 29–Feb 2: Washington, DC

  56. Hoetelmans RMW, Burger DM, Meenhorst PL, et al. Pharmacokinetic individualisation of zidovudine therapy: current state of pharmacokinetic-pharmacodynamic relationships. Clin Pharmacokinet 1996; 30(4): 314–327

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy Practice, College of Pharmacy, The University of Minnesota, 7-115 Health Sciences Unit F, 308 Harvard Street S.E., Minneapolis, Minnesota, 55455, USA

    Edward P. Acosta, Linda M. Page &  Courtney V. Fletcher

Authors
  1. Edward P. Acosta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Linda M. Page
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Courtney V. Fletcher
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Acosta, E.P., Page, L.M. & Fletcher, C.V. Clinical Pharmacokinetics of Zidovudine. Clin-Pharmacokinet 30, 251–262 (1996). https://doi.org/10.2165/00003088-199630040-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199630040-00001

Keywords

Search

Navigation